Eli Lilly & Co. Stock Underperforms Thursday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Eli Lilly & Co. (LLY) shares fell 4.55% to $1,154.97 on Thursday, underperforming the broader market and key competitors like Johnson & Johnson, Pfizer, and AbbVie despite a positive trading session for major indices. This marks the stock's second consecutive day of losses, with LLY closing 7.56% below its 52-week high. Trading volume matched its 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Eli Lilly & Co. (LLY) slipped 4.55% to $1,154.97 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 1.66% to 7,437.63 and the Dow Jones Industrial Average rising 1.19% to 52,208.06.
This was the stock's second consecutive day of losses.
Eli Lilly & Co. closed 7.56% below its 52-week high of $1,249.45, which the company reached on July 7th.
The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson (JNJ) fell 3.66% to $255.82, Pfizer Inc. (PFE) fell 0.95% to $24.91, and AbbVie Inc. (ABBV) fell 2.24% to $257.41.
Trading volume (3.0 M) eclipsed its 50-day average volume of 3.0 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 30, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-30-26 1631ET